ASX-Dividend-Report-Banner
Sponsored

Chimeric Therapeutics (ASX: CHM) advances ADVENT-AML trial to next cohort

June 05, 2024 11:29 AM AEST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Chimeric Therapeutics (ASX: CHM) advances ADVENT-AML trial to next cohort
Image source: Company update

Highlights

  • The ADVENT-AML trial of CHM CORE-NK progresses to the next cohort with approval from the safety monitoring committee.
  • The second cohort will evaluate a higher dose of CHM CORE-NK in patients with AML.
  • The trial is currently open for enrollment at The University of Texas MD Anderson Cancer Center.

Chimeric Therapeutics Limited (ASX: CHM) has announced a significant advancement in its Phase 1B ADVENT-AML trial, which is moving forward to the next cohort.

Data source: Company update

In the upcoming cohort, three patients with refractory or relapsed AML will receive CHM CORE-NK at dose level 2 in combination with venetoclax and azacitidine.

More about the ADVENT-AML Phase 1B trial

The ADVENT-AML Phase 1B trial is an investigator-initiated study.

Data source: Company update

Enrollment for the first cohort began in the first quarter of 2024. Three patients with refractory or relapsed AML were administered CHM CORE-NK at dose level 1 along with standard-of-care aza/ven. During the 28-day dose-limiting toxicities (DLT) assessment period, no DLTs were reported.

Following a thorough review of the data from these three patients, the safety monitoring committee authorised the trial to proceed to the next cohort.

CHM shares were trading at AU$0.017 apiece at the time of writing on 5 June 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.